SBIR/STTR Research Award
Development of Oxymorphone DETERx, an abuse-deterrent, extended-release opioid fo
Award amount
$472,811Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- COLLEGIUM PHARMACEUTICAL, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- DMDLZN7GH8R7
- Solicitation number
- DA14-013
- Topic code
- NIDA
Research abstract
DESCRIPTION: The overall objective of the research is to further the development of an abuse-deterrent formulation of the potent opioid analgesic oxymorphone utilizing the DETERx(R) platform technology. The DETERx technology is a patented formulation approach to abuse-deterrence that establishes physical and chemical barriers designed to avoid dose dumping when the formulation is subjected to a variety of common tampering techniques. The extended-release (ER) DETERx capsules contain microspheres that aredifficult to crush due to their small size and physical properties (microspheres are waxy and tend to fuse upon crushing), thereby preserving the ER characteristics following attempts at physical manipulation. Within the microspheres, the active opioid ismolecularly distributed as a hydrophobic complex in a waxy matrix, providing protection from rapid extraction in a variety of solvents even after physical manipulation. The unique microsphere formulation approach has been applied by Collegium Pharmaceutica
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)